Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2019

01.07.2019 | Epidemiology

Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II

verfasst von: Samantha Puvanesarajah, Susan M. Gapstur, Alpa V. Patel, Mark E. Sherman, W. Dana Flanders, Ted Gansler, Melissa A. Troester, Mia M. Gaudet

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In a screened population, breast cancer-specific mortality is lower for screen-detected versus symptom-detected breast cancers; however, it is unclear whether this association varies by follow-up time and/or tumor characteristics. To further understand the prognostic utility of mode of detection, we examined its association with breast cancer-specific mortality, overall and by follow-up time, estrogen receptor status, tumor size, and grade.

Methods

In the Cancer Prevention Study-II Nutrition Cohort, 3975 routinely screened women were diagnosed with invasive breast cancer (1992–2015). Among 2686 screen-detected and 1289 symptom-detected breast cancers, 206 and 209 breast cancer deaths, respectively, occurred up to 24 years post diagnosis. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated from Cox proportional hazard regression models.

Results

Controlling for prognostic factors, symptom detection was associated with higher risk of breast cancer-specific death up to 5 years after diagnosis (HR≤5years = 1.88, 95% CI 1.21–2.91) this association was attenuated in subsequent follow-up (HR>5years = 1.26, 95% CI 0.98–1.63). Within tumor characteristic strata, there was a 1.3–2.7-fold higher risk of breast cancer death associated with symptom-detected cancers ≤ 5 years of follow-up, although associations were only significant for women with tumors < 2 cm (HR≤5years = 2.42, 95% CI 1.19–4.93) and for women with grade 1 or 2 tumors (HR≤5years = 2.72, 95% CI 1.33–5.57). In subsequent follow-up, associations were closer to the null.

Conclusions

Screen detection is a powerful prognostic factor for short-term survival. Among women who survived at least 5 years after breast cancer diagnosis, other clinical factors may be more predictive of breast cancer survival.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Kerlikowske K (1997) Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. JNCI 22:79–86CrossRef Kerlikowske K (1997) Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. JNCI 22:79–86CrossRef
4.
Zurück zum Zitat Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. JNCI 91(23):2020–2028CrossRefPubMed Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. JNCI 91(23):2020–2028CrossRefPubMed
5.
Zurück zum Zitat Domingo L, Salas D, Zubizarreta R, Bare M, Sarriugarte G, Barata T, Ibanez J, Blanch J, Puig-Vives M, Fernandez A, Castells X, Sala M (2014) Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Res 16(1):R3. https://doi.org/10.1186/bcr3595 CrossRefPubMedPubMedCentral Domingo L, Salas D, Zubizarreta R, Bare M, Sarriugarte G, Barata T, Ibanez J, Blanch J, Puig-Vives M, Fernandez A, Castells X, Sala M (2014) Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Res 16(1):R3. https://​doi.​org/​10.​1186/​bcr3595 CrossRefPubMedPubMedCentral
7.
18.
Zurück zum Zitat Tabar L, Dean PB, Chen TH, Yen AM, Chen SL, Fann JC, Chiu SY, Ku MM, Wu WY, Hsu CY, Chen YC, Beckmann K, Smith RA, Duffy SW (2019) The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer 125(4):515–523. https://doi.org/10.1002/cncr.31840 CrossRefPubMed Tabar L, Dean PB, Chen TH, Yen AM, Chen SL, Fann JC, Chiu SY, Ku MM, Wu WY, Hsu CY, Chen YC, Beckmann K, Smith RA, Duffy SW (2019) The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer 125(4):515–523. https://​doi.​org/​10.​1002/​cncr.​31840 CrossRefPubMed
22.
Zurück zum Zitat Garfinkel L (1985) Selection, follow-up, and analysis in the American cancer society prospective studies. Natl Cancer Inst Monogr 67:49–52PubMed Garfinkel L (1985) Selection, follow-up, and analysis in the American cancer society prospective studies. Natl Cancer Inst Monogr 67:49–52PubMed
25.
Zurück zum Zitat Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC (2009) Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 101(8):1338–1344CrossRefPubMedPubMedCentral Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC (2009) Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 101(8):1338–1344CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A (1995) Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality, and histology. J Med Screen 2(2):94–98CrossRefPubMed Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A (1995) Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality, and histology. J Med Screen 2(2):94–98CrossRefPubMed
32.
33.
Zurück zum Zitat Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H (1997) Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 75(5):762–766CrossRefPubMedPubMedCentral Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H (1997) Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 75(5):762–766CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Kerlikowske K, Carney PA, Geller B, Mandelson MT, Taplin SH, Malvin K, Ernster V, Urban N, Cutter G, Rosenberg R, Ballard-Barbash R (2000) Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 133(11):855–863CrossRefPubMed Kerlikowske K, Carney PA, Geller B, Mandelson MT, Taplin SH, Malvin K, Ernster V, Urban N, Cutter G, Rosenberg R, Ballard-Barbash R (2000) Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 133(11):855–863CrossRefPubMed
38.
39.
Zurück zum Zitat Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E (2000) Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. JNCI 92(13):1081–1087CrossRefPubMed Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E (2000) Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. JNCI 92(13):1081–1087CrossRefPubMed
44.
Zurück zum Zitat Hortobagyi NGCJ, D’Orsi CJ et al (2017) AJCC Cancer Staging Manual, 8th edn. Springer, New York Hortobagyi NGCJ, D’Orsi CJ et al (2017) AJCC Cancer Staging Manual, 8th edn. Springer, New York
Metadaten
Titel
Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II
verfasst von
Samantha Puvanesarajah
Susan M. Gapstur
Alpa V. Patel
Mark E. Sherman
W. Dana Flanders
Ted Gansler
Melissa A. Troester
Mia M. Gaudet
Publikationsdatum
01.07.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05322-9

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Research and Treatment 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.